



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.
PHONE : 022-3045 1500 / 3045 1200
FAX : 022-2493 0534 / 2493 9633
<http://www.uniquepharma.com>

StockExchange-NSE letters/MM:SA:398

February 5, 2013

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051

Stock Symbol: JBCHEPHARM

Dear Sir,


Sub : Unaudited Financial Results for the quarter ended on December 31, 2012

Enclosed please find unaudited financial results for the quarter ended on December 31, 2012. These financial results have been approved and taken on record by the board of directors at its meeting held today.

We request you to take the above on record.

Thanking you,

Yours faithfully,
for J. B. Chemicals & Pharmaceuticals Limited


M. C. Mehta

Company Secretary - General Manager

Encl: As above



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.
PHONE : 022-3045 1500 / 3045 1200
FAX : 022-2493 0534 / 2493 9633
http://www.uniquepharma.com

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31/12/2012

Sl. No.	PART I - Particulars	(Rs. in lakhs)					
		Quarter ended			Nine months ended		Year ended
		31/12/2012	30/09/2012	31/12/2011	31/12/2012	31/12/2011	31/03/2012
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income from Operations						
	a. Net sales (Net of excise duty)	19,976.13	21,212.46	14,955.91	59,673.30	48,777.46	63,577.48
	b. Other Operating Income	453.10	511.72	587.50	1,454.61	4,386.52	5,064.65
	Total Income from Operations (Net) (a+b)	20,429.23	21,724.18	15,543.41	61,127.91	53,163.98	68,642.13
2	Expenses						
	a. Cost of materials consumed	6,509.73	7,337.08	4,877.16	19,979.60	15,705.25	20,320.53
	b. Purchases of stock-in-trade	1,947.23	1,711.79	1,391.45	5,055.79	4,182.87	6,999.76
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	11.44	216.10	428.22	582.09	1,162.50	(547.18)
	d. Employees benefits expense	2,905.61	2,892.84	2,257.89	8,877.98	7,499.15	10,131.32
	e. Depreciation and amortization expense	625.00	612.65	562.94	1,839.00	1,697.94	2,230.40
	f. Exchange Fluctuation Transactional (Gain)/Loss	638.87	136.61	595.18	1,671.40	455.37	1,736.63
	g. Other Expenses	5,855.38	6,245.95	4,581.94	17,218.09	14,882.22	22,276.72
	Total Expenses	18,493.26	19,153.02	14,686.78	55,223.95	45,905.30	63,148.18
3	Profit/(Loss) from Operations before Other Income, Finance Cost and exceptional item (1-2)	1,935.97	2,571.16	856.63	5,983.96	7,658.68	5,493.95
4	Other Income	700.89	1,368.40	624.60	2,339.30	2,405.57	2,851.19
5	Profit/(Loss) from Ordinary Activities before Finance Cost and exceptional item (3+4)	2,636.86	3,939.56	1,481.23	8,243.26	10,064.25	8,345.14
6	Finance Cost	187.97	95.66	553.57	407.76	1,934.51	2,163.97
7	Profit/(Loss) from Ordinary Activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	2,448.89	3,843.90	527.66	7,835.50	8,129.74	6,181.17
8	Exchange Fluctuation Translation Gain / (Loss)	674.86	942.55	(2,738.23)	655.64	(4,066.47)	(1,318.27)
9	Profit from Ordinary Activities after Exchange Fluctuation Translation Gain / (Loss) but before Exceptional item (7+-8)	3,123.75	4,786.45	(1,830.57)	8,491.14	4,863.27	4,862.90
10	Exceptional item	-	-	-	-	76,859.34	76,859.34
11	Profit from Ordinary Activities before Tax (9+10)	3,123.75	4,786.45	(1,838.57)	8,491.14	88,122.61	88,922.24
12	Tax expenses	936.35	886.08	(1,313.69)	1,972.52	16,739.23	16,652.30
13	Net Profit for the period from Ordinary Activities after Tax (11-12)	2,187.40	3,900.37	(516.88)	6,518.62	63,383.38	64,269.94
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,694.15	1,694.15	1,694.15	1,694.15	1,694.15	1,694.15
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	-	-	93,692.17
16	Earning per share (EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	2.58	4.60	(0.61)	7.70	74.90	75.95
	(2) Diluted	2.58	4.60	(0.61)	7.69	74.86	75.95

Sl. No.	PART II - Particulars	Quarter ended			Nine months		Year ended
		31/12/2012	30/09/2012	31/12/2011	31/12/2012	31/12/2011	31/03/2012
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	37,381,103	37,380,603	37,853,218	37,381,103	37,853,210	37,388,603
	- Percentage of shareholding	44.13	44.13	44.69	44.13	44.69	44.13
2	Promoters and Promoter Group Shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	47,326,197	47,326,697	46,854,090	47,326,197	46,854,098	47,326,697
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.87	55.87	55.31	55.87	55.31	55.87



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:
 "NEELAM CENTRE", 'B' WING, 4TH FLR.,
 HIND CYCLE ROAD, WORLI,
 MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.
 PHONE : 022-3045 1500 / 3045 1200
 FAX : 022-2493 0534 / 2493 9633
<http://www.uniquepharma.com>

B INVESTOR COMPLAINTS

Particulars	3 Months ended 31/12/2012
Pending at the beginning of the quarter	Nil
Received during the quarter	5
Disposed of during the quarter	5
Remaining unresolved at the end of the quarter	Nil

NOTES

- 1 The above financial results have been reviewed by the audit committee and approved by the board of directors at its meeting held on February 5, 2013.
- 2 The other operating income for the nine months period ended December 2011 included dividend of Rs.24.97 crores received from the company's Russian subsidiary.
- 3 The statutory auditors have carried out a limited review of the above unaudited financial results for the quarter and nine months ended on December 31, 2012.
- 4 The figures for the nine months ended on December 31, 2012 are strictly not comparable with the corresponding period in the previous year consequent to sale of Russia-CIS DTC business undertaking on July 14, 2011.
- 5 The company is engaged in a single segment of activity namely, "Pharmaceuticals".
- 6 Previous quarter's / period's figures have been regrouped / re-stated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B.Mody
 Chairman & Managing Director

Place : Mumbai
 Date : February 5, 2013